Candace Bushnell Leads More than 400 Runners at Seventh Annual 5K Race of Hope to Defeat Depression in Southampton, NY
Event Raises Over $325,000 for Depression Research
(August 8, 2022 – Southampton, NY) – The Hope for Depression Research Foundation’s (HDRF) Seventh Annual 5K Race of Hope brought together more than 400 men, women, and children on Sunday, August 7th in Southampton Village in support of mental health awareness and research. Iconic author and creator of the Sex and the City series, Candace Bushnell, cheered the crowd on as Celebrity Grand Marshal during the festive event, which raised over $325,000 for research into new and improved treatments for depression and anxiety.
HDRF founder Audrey Gruss and Board member Arthur Dunnam, both Hamptons residents, served with Bushnell as Co-Grand Marshals of the 5K walk/run, which is a USA Track and Field-sanctioned event.
“This organization is so important to me because I too, have suffered from depression and I can tell you that it robs people of a portion of their lives,” said Bushnell. “I’ve also had friends who have had mental illnesses and the outcome hasn’t always been good for them. This is a very personal cause for me and I’m so excited about the work that Audrey Gruss is doing to find new treatments.”
Audrey Gruss said, “Over 100 million people struggle with depression and anxiety since the pandemic. That’s a third of Americans including men, women and children. You are out here today to help raise awareness and help support one of the most prevalent health issues of our time.”
“For sixteen years we’ve raised awareness and done the research, and we’re on the way to finding a new antidepressant,” added Gruss. “Did you know that 50% of the people who need medication, don’t respond to what’s out there? Most of the available medications are over 35 years old, with Prozac being introduced in 1985. Now we’re working on a major new category of medication with clinical trials at Mount Sinai and Columbia, and your support today will help fund this critical research.”
At the starting gun, participants set off to complete the 3.1-mile course around Lake Agawam and the tree-lined streets of Southampton, NY. Hope was in abundant supply as everybody sported t-shirts and caps in HDRF’s signature sunshine yellow.
At the close of the race, Audrey Gruss handed out awards in several categories including First Prize for best male time went to William Hague, and First Prize for the best female time went to Kira Garry. The award for Top Fundraising Team went to Kim Heirston, which raised over $21,000. The award for Top Individual Fundraiser went to Arthur Dunnam, who raised $45,400 from friends and family for his race. The award for the largest team went to Natasha Jefferies and her team, Dakari’s Heartbeat, with 14 members.
All race participants received an HDRF branded ultra-lightweight jacket, hat, race shirt, and finisher medal. The first, second, and third place winners received cash prizes of up to $500. Successful fundraisers also received special prizes for raising upwards of $250 and $1,000.
Race participants included: Janna Bullock, Sharon Bush and Bob Murray, Jamee and Peter Gregory, Kim Heirston, Tania Higgins, Richard LeFrak, Anne Nordeman, John Paulson, James and Teresa Remez and their daughters Sofia and Lila, Mirella Cameran-Reilly, Southampton Village Mayor Jesse Warren and Lis Waterman.
5K Race of Hope Committee
Diamond Level: Tom Quick and Michael Donnell
Platinum Level: Dominique Buaron, Jamee & Peter Gregory, Judy & Leonard Lauder, Nicola & Jeffrey Marcus, Paulson Family Foundation and Nancy Silverman.
Gold Level: Felice & Shelley Bergman, David C. Bohnett, James R. Borynack & Adolfo Zaralegui/Findlay Galleries, Geoffrey Bradfield, Ide & David Dangoor, Arthur Dunnam & Roy Cohen, Annie & Michael Falk, Bambi & Roger, Felberbaum, The Honorable David Fischer & Jennifer Fischer, Frances & Jeff Fisher, Mary Ann Fribourg, Kim Heirston, Tania Higgins, Kontes Family, Susan Lloyd, Sharon & John Loeb, Jr., Robert F. Mancuso, Mary P. Moran, Laura Nicklas, Anne & Jacques Nordeman, Jane & Richard Novick, Kathy Prounis, Barbara & Randall Smith, Scott Snyder, Mary Ann Tighe & David Hidalgo and Lynne Wheat.
Silver Level: Bruce Bierman & William Secord, Serena & Brad Bowman, Jill Blanchard, Rita & Charles Bronfman, Bulgin & Associates, Janna Bullock, Sharon Bush & Bob Murray, Pilar &, Stephen Robert, Lisa & Sanford Ehrenkranz, Marjorie & Alexander Federbush, Kelli & Jerry Ford, Barbara & Alan Glatt, Mrs. Darcy Gould, Susan Gutfreund, Candy Hamm, Mai Hallingby Harrison, Yaz & Valentin Hernández, Gail Hilson, Ashley & Harriet Hoffman, Elizabeth & Edgar Howard, Natasha Jeffries, Carol Mack, Muffy & Donald Miller, Lucia N. Musso, Pamela Pantzer, Bonnie Pfeiffer Evans, Robin Pickett, Hilary Geary Ross, Nancy Schaffel, Carolyn & Curtis Schenker, Frances G. Scaife, Ginny & David Sydorick, Lydia Touzet, Nicholas Varney, Susan H. Warner, Lis Waterman, Clelia & Tom Zacharias and Silvia Zoullas.
5K Race of Hope Sponsors
Akris, Findlay Galleries, Gubbins Running, Jacob Antilety Landscaping, Juice Press, Livingston Builders, Scott’s Protein Balls, Southampton Arts Center, Stony Brook Southampton Hospital, Tammy Fender skincare.
About Hope for Depression Research Foundation:
Audrey Gruss founded HDRF in 2006 in memory of her mother Hope, who struggled with clinical depression. Today, HDRF is the leading nonprofit organization focused solely on advanced depression research into new and better treatments for the illness. The World Health Organization has declared depression as the leading cause of disability worldwide, and yet conventional medications today are outdated and do not fully work for 50% of patients. The mission of the HDRF is to spur innovative neuroscience research into the origins, medical diagnosis, new treatments, and prevention of depression and its related mood disorders – bipolar disorder, postpartum depression, post-traumatic stress disorder, anxiety disorder, and suicide. To date, HDRF has provided more than $45 million through over 200 grants for breakthrough depression research that promises to transform the way depression is viewed, diagnosed, treated and prevented. Currently, HDRF has a potential new class of medication in pilot clinical trials at Mount Sinai Medical Center and Columbia University.
On Friday, July 15th, Hope for Depression Research Foundation (HDRF) hosted a panel discussion on mental health at the Southampton Arts Center in Southampton Village, New York.
The hour-long discussion focused on The Four Pillars of Mental Health: Sleep, Diet, Exercise and Meditation. Over 80 people attended the event, which HDRF conceived in partnership with Southampton Arts Center (SAC) Board member Simone Levinson.
Panelists were Bob Roth, CEO of the David Lynch Foundation, Eddie Stern, yoga instructor and author, Jamie Pabst, founder and CEO of Spiritune and Ivey Leidy, nutrition expert and coach. The moderator was HDRF Executive Director Louisa Benton.
The event was a kick-off for the seventh annual Race of Hope to Defeat Depression, a 5K run/walk in August that raises funds for depression research. In her welcome remarks, HDRF Founding Chair Audrey Gruss said: “This discussion on evidence-based methods to reduce stress and increase resilience to anxiety is more important than ever. Mental illness and mental wellness are the reverse side of the same coin.”
A luncheon followed the panel discussion, and was exclusively for the committee members of the Race of Hope. Over 60 committee members attended including James R. Borynack and Adolfo Zaralegui, Janna Bullock, Arthur Dunnam and Roy Cohen, Mark Gilbertson, Alan Glatt, Jamee and Peter Gregory, Martin Gruss, Mai Hallingby Harrison, Kim Heirston, Natasha Jeffries, Sharon Loeb, Anne Nordeman, Kathy Prounis, Nancy Silverman, and Lis Waterman.
Luncheon Guests were seated at tables adorned with bright yellow sunflowers in the SAC Sculpture Garden, where they enjoyed a delicious buffet of grilled chicken kebabs, poached salmon, grilled vegetables, gourmet cheeses, farro salad, garden salad, red potato and string beans and fresh fruit kebabs. Juice Press donated fresh, healthy beverages.
Throughout the luncheon, models strolled among the tables wearing items from the Fall 2022 collection from Akris, a sponsor of the Race of Hope. After the luncheon, guest walked to the Akris boutique nearby on Jobs Lane for champagne, dessert bites, and gift bags.
In June more than 40 neuroscientists from the Hope for Depression Research Foundation (HDRF) Depression Task Force met in person at the University of Michigan, Ann Arbor for a three day annual retreat and summit. They shared exciting research updates and bonded as colleagues.
This was the seventh annual retreat for the Depression Task Force consortium, a major, multi-university effort to advance the understanding and treatment of depression. The scientists were grateful to be together after covid restrictions forced the meeting to be on zoom for the past two years.
“We need this community to tackle a complex problem like depression,” said Dr. Huda Akil, Professor of Neuroscience at the University of Michigan, who is a founding member of the Task Force. She pointed out that depression is a shadow pandemic on the heels of COVID.
The Depression Task Force consists of nine principal investigators, each of whom run large labs. The investigators are: Dr. Akil of Michigan, Dr. Eric Nestler of Mount Sinai, Dr. Helen Mayberg of Mount Sinai, Dr. Rene Hen of Columbia, Dr. Jonathan Javitch of Columbia, Dr. Michael Meaney of McGill University and Singapore Institute for Clinical Sciences, Dr. Elisabeth Binder of Germany’s Max Planck Institute, Dr. Conor Liston of Weill Cornell, and Dr. Kafui Dzirasa of Duke.
By extension, all of the junior scientists in these labs are also part of the Task Force consortium and appreciate it as career-defining opportunity. They have learned trust and seamlessly share information and research data even before it is published.
Each year the retreat allows the young scientists to interact, spark ideas, and benefit from being mentored by the principal investigators. The collaborative approach has propelled the science over the past decade, since 2012 when the DTF was formed.
“They’ve really shaped each other’s science in ways that is so rare,” said Dr. Joanna Louise Spencer-Segal, MD, Assistant Professor at the University of Michigan. “It keeps it fast, it keeps it relevant. It keeps people focused on the goal, which is drug discovery.”
While the days were packed with presentations on campus, Tuesday night dinner allowed for an excursion to Cornman Farms’ Red Barn just outside the city. There the scientists enjoyed wine and a gourmet meal served with the sunset pouring in the barn windows.
All the members of the Depression Task Force expressed thanks to Pamela Patterson, PhD, a young scientist in Dr. Akil’s lab, who organized the entire three-day event.
Cortney Turner is an Associate Research Scientist in the lab of
DTF member Dr. Huda Akil, University of Michigan.
I became interested in depression research because of my own personal experience. At age 14, my freshmen year of high school, I was hospitalized with severe depression. It was 1991, and the psychiatrists didn’t really know how to help me. I was put on Prozac and other antidepressants, none of which helped me. I decided to dedicate my life to research and finding better predictors and treatments for depression, so that others don’t have to go through what I went through.
I grew up an only child in a trailer park in rural Ohio. My mother was a Type I diabetic, and my father is a Vietnam Veteran from Kentucky. I graduated Salutatorian and went on to attend Bowling Green State University, where I graduated Phi Beta Kappa with a dual-degree B.S. in biology and psychology. I earned a Ph.D. in Medical Sciences with a concentration in Neuroscience at the University of Florida.
For postdoctoral work, I happily ended up in the lab of Dr. Huda Akil at the University of Michigan. My research with Hope for Depression Research Foundation directly addresses the mental health crisis we see in youth, worsened by the pandemic. I focus on stress vulnerability and resilience in college freshmen; we’ve now collected data on three cohorts of students who have experienced the pandemic during their freshman year.
Overall levels of depression are higher in these freshman classes, but we also note a subset of students who appear resilient to the stress hits. We are analyzing a combination of genetic, physiological, psychological and behavioral data so we can better understand this resilience and how to promote it.
We are also creating predictive algorithms based on the data that can tell us who is more likely to develop anxiety or depression during this stressful time. The knowledge will be a catalyst for new ways to prevent and treat depression in these students, and in the population at large.
May is Mental Health Awareness Month
In honor of this important month, we want to share the latest exciting news from our research labs. HDRF’s mission to advance the understanding and treatment of depression has never been more urgent.
In fall 2020, the Hope for Depression Research Foundation began a clinical trial of tianeptine, which represents a brand new category of antidepressant. The trial is underway at Columbia University and Mount Sinai Medical Center, and at this writing shows early promising results.
The trial is focused on patients who are treatment-resistant — they have not responded to the conventional medications available today. The scientists in our Depression Task Force (DTF) are testing the hypothesis that a certain profile of these patients will respond dramatically to tianeptine because of their specific brain chemistry . These patients will have two evident symptoms: 1) they have a behavioral symptom known as rejection sensitivity, or a blunted ability to cope with the psychosocial stress of rejection (i.e. losing a job or promotion, ending a relationship) and 2) they have disrupted activity in a specific rejection and pain circuit in the brain, as detected by a brain scan.
The subjects are being give tianeptine because this compound has a unique ability — discovered by DTF scientists — to repair deficits in the rejection and pain circuit through targeted molecular action. The DTF believes that depression will remit as the physical circuit is repaired, and it’s also possible that the behavioral symptom of hyper-sensitivity to rejection will be alleviated.
By repairing circuit deficits at a fine-tuned location, tianeptine may finally help patients where other medications have failed. If the trial is successful, it will lead to a new precision medicine approach to depression that will greatly increase response rates by pairing patients with the right treatment for their underlying biology.
Clinical trials began October 2020 and patient recruitment has been extended to 2023 to reach a study goal of 75 patients. Early results are extremely encouraging, and the teams are actively recruiting patients to continue the work. The study seeks men and women ages 21-60 who have not responded to standard antidepressant medication.